Surveillance and management of multidrug-resistant microorganisms
- 1 August 2011
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Review of Anti-infective Therapy
- Vol. 9 (8), 653-679
- https://doi.org/10.1586/eri.11.77
Abstract
Multidrug-resistant organisms are an established and growing worldwide public health problem and few therapeutic options remain available. The traditional antimicrobials (glycopeptides) for multidrug-resistant Gram-positive infections are declining in efficacy. New drugs that are presently available are linezolid, daptomicin and tigecycline, which have well-defined indications for severe infections, and talavancin, which is under Phase III trial for hospital-acquired pneumonia. Unfortunately the therapies available for multidrug-resistant Gram-negatives, including carbapenem-resistant Pseudomonas aeruginosa, Acinetobacter baumannii and Enterobacteriaceae, are limited to only colistin and tigecycline. Both of these drugs are still not registered for severe infections, such as hospital acquired pneumonia. Consequently, as confirmed by scientific evidence, a multidisciplinary approach is needed. Surveillance, infection control procedures, isolation and antimicrobial stewardship should be implemented to reduce multidrug-resistant organism diffusion.Keywords
This publication has 251 references indexed in Scilit:
- Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time–kill assayInternational Journal of Antimicrobial Agents, 2011
- Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological studyThe Lancet Infectious Diseases, 2010
- The in vitro evaluation of tigecycline tested against pathogens isolated in eight countries in the Asia-Western Pacific region (2008)Journal of Infection, 2010
- Hospital-Acquired Infections Due to Gram-Negative BacteriaNew England Journal of Medicine, 2010
- Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trialThe Lancet, 2010
- Risk Factors and Clinical Impact of Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniaeInfection Control & Hospital Epidemiology, 2009
- Long-term control of hospital-wide, endemic multidrug-resistant Acinetobacter baumannii through a comprehensive “bundle” approachAmerican Journal of Infection Control, 2009
- The burden of vancomycin-resistant enterococcal infections in US hospitals, 2003 to 2004Diagnostic Microbiology and Infectious Disease, 2008
- The Use of Active Surveillance Cultures in Adult Intensive Care Units to Reduce Methicillin‐ResistantStaphylococcus aureus–Related Morbidity, Mortality, and Costs: A Systematic ReviewClinical Infectious Diseases, 2008
- Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concernThe Lancet Infectious Diseases, 2008